A new synthetic strategy for the asymmetric synthesis of five-membered spiropyrazolones via N-heterocyclic carbene-catalyzed [3+2] annulations employing enals and unsaturated pyrazolones as substrates has been developed. The new protocol allows the flexible variation of all four substituents of the pharmaceutically important spiropyrazolones in moderate to very good yields and in most cases with excellent diastereoselectivities and good to excellent enantioselectivities.
Since the first enantioselective carbon-carbon bond formations catalyzed by N-heterocyclic carbenes (NHCs) in the case of the benzoin condensation reported by Sheehan and Hunnemann in 1966, 1a and the first enantioselective Stetter reaction developed by our group in the late eighties, 1b,c the field of asymmetric NHC-organocatalysis 2 has grown rapidly being now an important chapter of Lewis-base organocatalysis.
In recent years, pyrazolones and related derivatives turned out to display a wide range of biological and pharmaceutical activities, 3 especially the spiropyrazolone derivatives. For example, spiropyrazolone A shows anticancer activity, 4a whereas spiro compounds B and C possess phosphodiesterase inhibitor activity (Figure 1 ). 4b,c Many organocatalytic asymmetric methods have been developed for the asymmetric synthesis of this important heterocyclic core structure, owing to the wide existence of the pyrazolone scaffold in related bioactive compounds. 5 Recently, NHCs have also been employed for the asymmetric synthesis of spiropyrazolone derivatives. In this context, Biju's group reported a formal [3+3] annulation reaction of α,β-unsaturat-ed aldehydes with α-arylidenepyrazolinones under oxidative NHC catalysis (Scheme 1, a). 6 Very recently, our group has developed an asymmetric multicomponent one-pot synthesis of spiropyrazolones using NHC organocatalysis (Scheme 1, b) . 7 Based on our previous work, herein we report a new strategy for the asymmetric synthesis of spiropyrazolones using unsaturated pyrazolones and enals as substrates via an NHC-catalyzed [3+2] annulation reaction. This new protocol allows the flexible variation of all four substituents R 1 -R 4 (Scheme 1, c).
Figure 1 Selected pharmaceutically active spiropyrazolones
We started our studies with the unsaturated pyrazolone 1a and cinnamaldehyde (2a) as test substrates in dichloromethane at room temperature (Table 1) . Initially, we obtained the spiropyrazolone product 3a in 45% yield with excellent diasteroselectivity when the achiral pre-catalyst 4a was employed. A series of chiral NHC pre-catalysts (Table 1 , entries 2-6) was screened encouraged by the initial result and showed that the pre-catalyst 4b was the best one. The optimization studies of the bases (entries 7-13) revealed that Cs 2 CO 3 gave the procuct 3a with the improved ee of 94% but with a 1:1 diastereomeric ratio (entry 7). When DMAP was employed as base (entry 11), the ee value was virtually the same (93%), but the reaction occurred with excellent diastereoselectivity in moderate yield. Using 4b as catalyst and DMAP as base, different solvents were screened and it turned out that DCE provided the desired SYNTHESIS0 0 3 9 -7 8 8 1 1 4 3 7 -2 1 0 X © Georg Thieme Verlag Stuttgart · New York 2017, 49, 1808-1815 paper Paper Syn thesis product 3a in very good yield (71%), as well as with excellent diastereoselectivity (dr >20:1) and enantiomeric excess of 93% ee (entry 18).
With the optimized reaction conditions in hand, the scope of the reaction substrates was investigated. First, a variety of enals were tested and the unsubstituted cinnamaldehyde worked very well under the standard conditions giving the product 3a. When enals with electron-donating and electron-withdrawing groups at the para-position were used, the spirocyclopentane pyrazolones 3b and c were obtained in moderate to good yields and with very good diastereo-and enantioselectivities. Other enal derivatives, bearing a 2-furyl and 1-propenyl group as R 4 were also tolerated and gave the desired products 3d and e in moderate to good yields and with very good to excellent ee and dr values (Scheme 2).
The relative and absolute configuration of the spiropyrazolone 3p was determined by X-ray crystal structure analysis ( Figure 2 ), 8 and the configuration of all other products 3 was assigned accordingly.
Subsequently, the variation of the unsaturated pyrazolones 1 was investigated. Substitution at the otho-position as well as para-position of the phenyl ring of R 1 resulted in the smooth conversion to the spiropyrazolones 3f,g in good yields and with excellent ee and dr. Moreover, instead of the phenyl ring, the indole group, 2-furyl group, and a 1-propenyl group furnished the desired products 3h-j in good yields and with very good to excellent ee values. The substrate scope was further evaluated by screening different substituents R 2 and R 3 . Various pyrazolones with aliphatic R 2 -substituents afforded the corresponding spiropyra-zolone products 3k-m in good yields and with enantioselectivities under virtually complete diastereoselectivities (dr ≥20:1). This was also true for the variation of the N-substituent R 3 (3n-q). Only in the case of R 2 = Me and R 3 = pchlorophenyl, a lower yield and stereoselectivity was observed (Scheme 3). pre-cat. 4 (10 mol%) base (1 equiv)
Scheme 1 Selected strategies for the asymmetric synthesis of spiropyrazolones
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A plausible catalytic cycle of the NHC-catalyzed [3+2] annulation of enals and unsaturated pyrazolones is depicted in Scheme 4. First, the deprotonation of the pre-catalyst with DMAP generates the free NHC-catalyst, which react with the enals 2 to form the Breslow intermediate I. This homoenolate equivalent then undergoes a Michael addition with the pyrazolones 1 to afford the acyl azolium intermediate II, which cyclizes to the spiropyrazolone product 3 and returns the catalyst (Scheme 4).
In summary, the asymmetric NHC-catalyzed [3+2] annulation of enals and unsaturated pyrazolones affords the corresponding spirocyclpentane pyrazolones in moderate to very good yields (up to 86%), in most cases with excellent diastereoselectivities (dr >20:1) and very good to excellent enantioselectivities (up to 95% ee) with broad substrate scope. The new variant allows the flexible variation of all four substituents as well. Unless otherwise noted, all commercially available compounds were used without further purification. Anhyd CH 2 Cl 2 was purified by distillation over CaH 2 . The products were purified by column chroma-Scheme 2 Substrate scope of the spiropyrazolones (variation of the enals)
pre-cat. 4b (10 mol% Paper Syn thesis tography on Merck silica gel 60, particle size 0.040-0.063 mm (230-240 mesh, flash). For TLC analysis, Merck precoated TLC plates (silica gel 60 GF254 0.25 mm) were used. Visualization of the developed TLC plates was performed with ultraviolet irradiation (254 nm). Optical rotation values were measured on a PerkinElmer 241 polarimeter. High-resolution mass spectra (HRMS) were acquired on a Ther-moFisher Scientific LTQ-Orbitrap XL. IR spectra (cm -1 ) were taken on a PerkinElmer Spectrum 100 FT-IR Spectrometer. 1 H NMR and 13 C NMR spectra were recorded at r.t. on Inova 400 or Agilent VNMRS 600 spectrometers. Chemical shifts (δ) are given in ppm relative to solvent residual peak (CDCl 3 , δ = 7.26) as external standard. Standard abbreviations for denoting multiplicities were used. Analytical HPLC was performed on a Hewlett-Packard 1100 Series instrument using chiral stationary phases [Daicel IC, Daicel AD, Daicel IA, Merck (S,S)-Whelk 01]. The melting point was obtained with a LLG MPM-H2 apparatus. The carbene catalysts 4a-f, 9 the unsaturated pyrazolones 10 and the corresponding cinnamaldehydes 11 were prepared according to literature procedure. The racemic samples of the spiropyrazolones 3 were prepared by using the racemic pre-catalyst 4a with DMAP.
Spiropyrazolones; General Procedure
A dried and argon-filled Schlenk tube was charged with the unsaturated pyrazolone 1 (0.4 mmol, 1.0 equiv) and triazolium salt 4b (0.04 mmol, 10 mol%) in anhydrous 1,2-dichloroethane (2 mL). Subsequently, the α,β-unsaturated aldehyde 2 (0.8 mmol, 2.0 equiv) and DMAP (0.4 mmol, 1.0 equiv) were introduced. The resulting mixture was stirred at r.t. for 12 h, and the reaction was completed as monitored by TLC. After purification by column chromatography on silica gel (pentane/EtOAc, 15:1), the desired spirocyclopentane pyrazolones 3 were obtained as yellow oils (3a-o,q,r) or as a colorless solid (3p). HPLC: Chiralpak IB, n-heptane/i-PrOH (9:1), 1.0 mL/min, t R (minor) = 5.16 min, t R (major) = 7.23 min; T = 30 °C; 95% ee. IR (ATR): 3363, 2969, 2320, 1740, 1607, 1496, 1367, 1220, 1035, 948, 852, 746 , 682 cm -1 . 13 C NMR (150 MHz, CDCl 3 ): δ = 205. 6, 168.5, 165.8, 158.7, 137.6, 136.2, 135.0, 131.8, 128.8 (2 C) , 128.4 (2 C), 127. 8, 126.4 (2 C), 125.4, 123.9, 119.3 (2 C), 114.3 (2 C), 75.7, 55.5, 55.3, 46.0, 43.8, 36.3, 29.5 (3 C) . HPLC: Chiralpak IB, n-heptane/EtOH (9:1), 1.0 mL/min, t R (minor) = 4.34 min, t R (major) = 5.12 min; T = 30 °C; 94% ee. IR (ATR): 3461, 2966, 2320, 1742, 1596, 1490, 1369, 1297, 1203, 1088, 960, 826, 749, 686 3 ]. 13 C NMR (150 MHz, CDCl 3 ): δ (major) = 204.9, 168.4, 165. 6, 138.4, 135.9, 135.3, 133.1, 130.2, 129.2, 129.1 (2 C), 128.9, 128.8, 128.7, 128.5, 128.0, 126.5, 126.4, 125.5, 123.4, 120.8, 119.3 (2 C), 75.6, 55.4, 45.6, 43.9, 36.3, 29.5 (3 C) . (5S,8S,9R)-4-(tert-Butyl)-8-(furan-2-yl)-2-phenyl-9-[(E)-styryl]-2,3-diazaspiro[4.4]non-3-ene-1,6-dione (3d) Compound 3d was isolated after flash chromatography (n-pentane/EtOAc, 20:1); yield: 101 mg (56%); pale yellow oil; [α] D 27 +290.8 (c = 0.5, CHCl 3 ).
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Scheme 4 Proposed catalytic cycle of the asymmetric spiropyrazolone synthesis
HPLC: Chiralpak IB, n-heptane/EtOH (9:1), 1.0 mL/min, t R (minor) = 10.65 min, t R (major) = 8.73 min; T = 30 °C; 91% ee. IR (ATR): 3458, 2970, 2328, 1739, 1366, 1216, 1095, 906, 752, 687 13 C NMR (150 MHz, CDCl 3 ): δ (major) = 204. 7, 168.4, 165.8, 152.4, 142.0, 137.6, 136.2, 135.1, 128.8 (2 C), 128.5 (2 C), 127.9, 126.4 (2 C), 125.4, 123.7, 119.2 (2 C), 110.4, 107.8, 75.2, 52.4, 42.9, 38.4, 36.3, 29.4 (3 C) . 
HRMS (ESI
(5S,8R,9R)-4-(tert-Butyl)-2-phenyl-8-[(E)-prop-1-en-1-yl]-9-[(E)styryl]-2,3-diazaspiro[4.4]non-3-ene-1,6-dione (3e)
Compound 3e was isolated after flash chromatography (n-pentane/EtOAc, 20:1); yield: 77 mg (45%); pale yellow oil; [α] D 27 +282.8 (c = 0.5, CHCl 3 ).
HPLC: Chiralpak AD, n-heptane/i-PrOH (97:3), 1.0 mL/min, t R (minor) = 10.56 min, t R (major) = 9.29 min; T = 30 °C; 86% ee. IR (ATR): 3370, 2967, 2318, 1696, 1598, 1491, 1369, 1296, 1201, 1088, 961, 825, 749 , 686 cm -1 . 1 H NMR (600 MHz, CDCl 3 ): δ = 7.87-7. 85 (m, 2 H, ArH), 2 H, ArH), 6 H, ArH), 6.48 (d, J = 15.9 Hz, 1 H, ArH), 6.21 (dd, J = 15.9, 8.6 Hz, 1 H, ArH), 1 H, CH=CHPh), 1 H, CHCH=CH), 3.71 (td, J = 11.5, 5.8 Hz, 1 H, CHCH=CH), 3.48 (dd, J = 11.5, 8.6 Hz, 1 H, CHCH 2 ), 2.92 (dd, J = 19.0, 8.6 Hz, 1 H, CHHCO), 2.48 (dd, J = 19.0, 11.5 Hz, 1 H, CHHCH), 3 H, CH 3 ), 1.33 [s, 9 H, C(CH 3 ) 3 ]. 13 C NMR (150 MHz, CDCl 3 ): δ = 205.9, 168. 5, 165.8, 134.9, 130.4, 128.7 (2 C), 128.5 (2 C), 128.4 (2 C), 127.8, 126.5 (2 C), 125.3, 124.4, 119.2 (2 C), 75.3, 53.9, 44.3, 41.7, 36.3, 29.4 
(5S,8S,9R)-4-(tert-Butyl)-9-[(E)-4-methoxystyryl]-2,8-diphenyl-2,3-diazaspiro[4.4]non-3-ene-1,6-dione (3f)
Compound 3f was isolated after flash chromatography (n-pentane/EtOAc, 20:1); yield: 108 mg (55%); yellow oil; [α] D 27 +260.4 (c = 0.5, CHCl 3 ).
HPLC: Chiralpak AD, n-heptane/i-PrOH (97:3), 1.0 mL/min, t R (minor) = 24.64 min, t R (major) = 20.12 min; T = 30 °C; 95% ee. IR (ATR): 3454, 2930, 2320, 1740, 1598, 1493, 1368, 1223, 1117, 958, 752, 688 1.38 [s, 9 H, C(CH 3 ) 3 ]. 13 C NMR (150 MHz, CDCl 3 ): δ = 205. 7, 168.6, 165.8, 159.4, 140.0, 137.6, 134.4, 129.0 (2 C), 128.9, 128.8, 128.7, 127.6 (2 C) , 127.5 (2 C), 127.3, 125.4, 121.4, 119.3 (2 C), 113.8 (2 C), 75.8, 55.4, 55.3, 45.9, 44.5, 36.3, 29.5 (3 C (5S,8S,9R)-4-(tert-Butyl)-9-[(E)-2-methoxystyryl]-2,8-diphenyl-2,3-diazaspiro[4.4]non-3-ene-1,6-dione (3g) Compound 3g was isolated after flash chromatography (n-pentane/EtOAc, 20:1); yield: 158 mg (80%); pale yellow oil; [α] D 27 +257.7 (c = 6.2, CHCl 3 ).
HPLC: Chiralpak IA, n-heptane/i-PrOH (9:1), 0.7 mL/min, t R (minor) = 9.74 min, t R (major) = 11.34 min; T = 30 °C; 92% ee. IR (ATR): 3483, 2964, 2304, 2079, 1969, 1879, 1748, 1689, 1594, 1468, 1367, 1296, 1244, 1191, 1122, 1031, 958, 841, 751, 686 13 C NMR (151 MHz, CDCl 3 ): δ = 205. 8, 168.6, 165.9, 156.6, 140.1, 137.7, 130.0, 128.9 (2 C) , 128.8 (2 C), 127.6 (2 C), 127.3 (2 C), 126.9, 125.5, 125.3, 124.2, 120.5, 119.2 (2 C), 110.9, 75.8, 55.7, 55.3, 46.1, 44.4, 36.3, 29.6 (3 C) . 
HRMS (ESI
(5S,8S,9R)-9-[(E)-2-(1H-Indol-2-yl)vinyl]-4-(tert-butyl)-2,8-diphenyl-2,3-diazaspiro[4.4]non-3-ene-1,6-dione (3h)
Compound 3h was isolated after flash chromatography (n-pentane/EtOAc, 20:1); yield: 96 mg (48%); pale yellow oil; [α] D 27 +292.7 (c = 0.5, CHCl 3 ).
HPLC: Chiralpak IC, n-heptane/EtOH (97:3), 1.0 mL/min, t R (minor) = 7.06 min, t R (major) = 5.07 min; T = 30 °C; 87% ee. IR (ATR): 3352, 2323, 2096, 1727, 1644, 1370, 1279, 1218, 1116 , 681 cm -1 . 1 H NMR (600 MHz, CDCl 3 ): δ = 8.16 (br s, 1 H, NH), 2 H, ArH), 1 H, ArH), 4 H, ArH), 2 H, ArH), 1 H, ArH), 2 H, ArH), 1 H, ArH), 1 H, ArH), 6.28 (dd, J = 2.1, 1.0 Hz, 1 H, ArH), 6.21 (d, J = 16.1 Hz, 1 H, CH=CHPh), 1 H, CHCH=CH), 4.34 (td, J = 11.7, 8.5 Hz, 1 H, CHCH=CH), 3.93 (dd, J = 11.2, 8.7 Hz, 1 H, CHCH 2 ), 3.20 (dd, J = 19.4, 8.5 Hz, 1 H, CHHCO), 2.89 (dd, J = 19.4, 12.1 Hz, 1 H, CHHCH), 1.41 [s, 9 H, C(CH 3 ) 3 ]. 13 C NMR (150 MHz, CDCl 3 ): δ = 205. 1, 168.6, 165.9, 139.6, 137.5, 136.7, 134.5, 129 .0 (2 C), 128.9 (2 C), 128.3 (2 C), 127.5 (2 C), 125.8, 125.6, 123.0, 121.7, 120.6, 120.1, 119.3 (2 C), 110.7, 103.9, 75.8, 55.4, 45.8, 44.8, 36.4, 29.5 (3 C) . 
HRMS (ESI
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Syn thesis (5S,8S,9R)-4-(tert-Butyl)-9-[(E)-2-(furan-2-yl)vinyl]-2,8-diphenyl-2,3-diazaspiro[4.4]non-3-ene-1,6-dione (3i)
Compound 3i was isolated after flash chromatography (n-pentane/EtOAc, 20:1); yield: 92 mg (51%); yellow oil; [α] D 27 +356.5 (c = 0.5, CHCl 3 ).
HPLC: Chiralpak IA, n-heptane/EtOH (97:3), 1.0 mL/min, t R (minor) = 15.28 min, t R (major) = 14.11 min; T = 30 °C; 94% ee. IR (ATR): 3461, 2964, 2331, 1743, 1597, 1490, 1368, 1211, 1113, 952, 749 , 689 cm -1 . 1 H NMR (600 MHz, CDCl 3 ): δ = 7. 2 H, ArH), 7 H, ArH), 2 H, ArH), 6.25 (dd, J = 3.3, 1.8 Hz, 1 H, ArH), 6.14 (dd, J = 15.9, 8.5 Hz, 1 H, CH=CHPh), 6.05 (d, J = 3.3 Hz, 1 H, ArH), 5.98 (d, J = 15.9 Hz, 1 H, CHCH=CH), 4.33 (td, J = 11.7, 8.5 Hz, 1 H, CHCH=CH), 3.86 (dd, J = 11.3, 8.5 Hz, 1 H, CHCH 2 ), 3.18 (dd, J = 19.3, 8.4 Hz, 1 H, CHHCO), 2.83 (dd, J = 19.3, 12.1 Hz, 1 H, CHHCH), 1.38 [s, 9 H, C(CH 3 ) 3 ]. 13 C NMR (150 MHz, CDCl 3 ): δ = 205.4, 168.3, 165.6, 151.5, 142.1, 139.9, 137.6, 128.9 (2 C), 128.8, 127.5 (2 C), 127.4 (2 C), 125.4, 122.9, 122.1, 119.3 (2 C), 111.1, 108.3, 75.6, 55.0, 46.0, 44.4, 36.3, 29.5 (3 C) . IR (ATR): 3482, 2967, 2297, 2061, 1952, 1748, 1694, 1595, 1493, 1368, 1294, 1198, 1124, 1061, 986, 941, 849, 754, 687 13 C NMR (150 MHz, CDCl 3 ): δ (major) = 205. 7, 168.5, 165.8, 140.1, 137.7, 135.3, 130.6, 130.2, 128.8 (2 C), 128.5, 127.5 (2 C), 127.2 (2 C), 125.3, 124.0, 119.2 (2 C), 75.7, 54.9, 46.1, 44.4, 36.2, 29.5 (3 C) 
HRMS (ESI
(5S,8S,9R)-4-Methyl-2,8-diphenyl-9-[(E)-styryl]-2,3-diazaspiro[4.4]non-3-ene-1,6-dione (3k)
Compound 3k was isolated after flash chromatography (n-pentane/EtOAc, 20:1); yield: 77 mg (71%); pale yellow oil; [α] D 20 +54.5 (c = 1.7, CHCl 3 ).
HPLC: Chiralpak AS, n-heptane/i-PrOH (9:1), 1.0 mL/min, t R (minor) = 6.20 min, t R (major) = 8.29 min; T = 30 °C; 85% ee. IR (ATR): 3437, 3030, 2927, 2847, 2635, 2324, 2101, 1894, 1712, 1594, 1495, 1450, 1368, 1304, 1222, 1076, 1020, 897, 838, 754 , 694 cm -1 . CH=CHPh), 6.17-6.13 (m, 1 H, CHCH=CH), 4.37 (td, J = 11.2, 9.0 Hz, 1 H, CHCH=CH), 3.46 (dd, J = 11.2, 8.5 Hz, 1 H, CHCH 2 ), 3.27 (dd, J = 19.6, 9.0 Hz, 1 H, CHHCO), 2.72 (dd, J = 19.6, 11.2 Hz, 1 H, CHHCH), 2.19 (s, 3 H, CH 3 ). 13 C NMR (151 MHz, CDCl 3 ): δ = 205.0, 167.9, 157. 2, 139.8, 137.4, 135.9, 135.1, 128.9 (2 C), 128.8 (2 C) , 128.5 (2 C), 128.0 (2 C), 127.4 (2 C), 126.5 (2 C), 125.5, 123.3, 119.3 (2 C), 75.7, 55.7, 46.0, 43.7, 14.4 . HPLC: Chiralpak IB, n-heptane/i-PrOH (9:1), 0.7 mL/min, t R (minor) = 10.02 min, t R (major) = 9.31 min; T = 30 °C; 86% ee. IR (ATR): 3440, 3031, 2925, 2647, 2321, 2098, 1992, 1887, 1694, 1595, 1494, 1455, 1350, 1227, 1137, 1061, 961, 901, 834, 751, 691 13 C NMR (151 MHz, CDCl 3 ): δ = 205. 2, 168.1, 161.0, 139.8, 137.6, 135.9, 135 .0, 128.9 (2 C), 128.8 (2 C), 128.5 (2 C), 127.9 (2 C), 127.4 (2 C), 126.5 (2 C), 125.5, 123.4, 119.3 (2 C), 75.6, 55.6, 46.1, 43.8, 22.2, 9.6 . Compound 3m was isolated after flash chromatography (n-pentane/EtOAc, 20:1); yield: 90 mg (50%); yellow oil; [α] D 20 +188.9 (c = 2.7, CHCl 3 ).
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HPLC: Chiralpak IB, n-heptane/i-PrOH (9:1), 0.7 mL/min, t R (minor) = 8.73 min, t R (major) = 7.92 min; T = 30 °C; 80% ee. IR (ATR): 3031, 2971, 2324, 2098, 1953, 1880, 1748, 1691, 1596, 1494, 1455, 1345, 1240, 1130, 1065, 963, 905, 837, 749 , 689 cm -1 . 1 H NMR (600 MHz, CDCl 3 ): δ = 7.86 (d, J = 7.7 Hz, 2 H, ArH), 7.41-7.37 (m, 2 H, ArH), 2 H, ArH), 2 H, ArH), 1 H, ArH), 3 H, ArH), 3 H, ArH), 2 H, CH=CH), 4.33 (td, J = 11.6, 8.5 Hz, 1 H, CHCH=CH), 3.57 (dd, J = 11.4, 6.5, Hz, 1 H, CHCH 2 ), 3.22 (dd, J = 19.4, 8.5 Hz, 1 H, CHHCO), 2.82-2.74 (m, 2 H, CHHCH), 1.36 (d, J = 6.9 Hz, 3 H, CCH 3 ), 1.31 (d, J = 6.9 Hz, 3 H, CCH 3 ). 13 C NMR (151 MHz, CDCl 3 ): δ = 205. 1, 168.2, 164.1, 139.7, 137.6, 136.0, 135.0, 128.9 (2 C), 128.8 (2 C) , 128.5 (2 C), 127.9 (2 C), 127.4 (2 C), 126.4 (2 C), 125.4, 123.7, 119.3 (2 C), 75.6, 55.3, 46.2, 44.2, 29.3, 21.3, 19.8 . 
